Conferences - Results from #280

Viewing 281-300 of 11879 articles

ESMO 2024: DLL-3 Targeted Therapy for Neuroendocrine Prostate Cancer

ESMO 2024: Outcomes with Novel Combinations in Non-Clear Cell RCC: ORACLE Study

ESMO 2024: Prospective COTRIMS (COlogne Trial of Retroperitoneal Lymphadenectomy in Metastatic Seminoma) Trial – 3 Year Update

ESMO 2024: Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC Patients

ESMO 2024: Does Lower Serum Testosterone Predict Metastases-Free Survival in nmCRPC Patients Treated with Novel Antiandrogens? a Post-Hoc Analysis of SPARTAN and ARAMIS

ESMO 2024: Determination of Tumor PSMA Expression in Prostate Cancer from Blood Using a Novel Epigenomic Liquid Biopsy Platform

ESMO 2024: Surveillance/minimal Intervention for Good Risk Disease

ESMO 2024: B7-H3 as Therapeutic Target for Prostate Cancer

ESMO 2024: Assessment of the Utility of CT Scans in the Long-Term Follow-up of Metastatic Non-Seminomatous Germ Cell Tumors: The Late CT Study

ESMO 2024: TAMARACK: Randomized Phase 2 Trial of the B7-H3 Targeting Antibody Drug Conjugate Vobramitamab

ESMO 2024: SAABR: Single Arm Phase II Study of Androgen Receptor Pathway Inhibitor + Atezolizumab + GnRH analog and Stereotactic Body Radiotherapy to the Prostate in Men with De Novo Hormone-sensitive Metastatic Prostate Cancer

ESMO 2024: Association of PD-L1 Expression with Clinical Response to TAR-200 in the Phase 2b SunRISe-1 Trial

ESMO 2024: Intensification of Systemic Treatment for Poor Risk Disease

ESMO 2024: The STAMPEDE2 (177Lu-PSMA-617) Trial: A Phase III, Randomised, Open-Label Trial in Patients with Metastatic Prostate Cancer Starting ADT

ESMO 2024: The STAMPEDE2 Stereotactic Ablative Body Radiotherapy Trial: A Phase III, Randomized, Open-Label Trial in Patients with Newly Diagnosed Oligometastatic Prostate Cancer Starting ADT

ESMO 2024: The STAMPEDE2 Niraparib-Abiraterone Acetate + Prednisolone Trial: A Phase III, Randomized, Open-Label Trial in Patients with Metastatic Prostate Cancer with a Deleterious Alteration in a HRR Gene Starting ADT

ESMO 2024: LEGEND: A Phase 1/2 Study of EG-70 (Detalimogene Voraplasmid) Intravesical Monotherapy for Patients with BCG-Unresponsive NMIBC with CIS

ESMO 2024: Phase 1/2 Trial of Oral Masofaniten (EPI-7386) in Combination with Enzalutamide Compared to Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer

ESMO 2024: Enzalutamide with or Without Leuprolide in Patients with High-Risk Biochemically Recurrent Prostate Cancer: EMBARK Post Hoc Analysis by Age

ESMO 2024: PSMA-PET and PROMISE Re-Define Stage and Risk in Patients with Prostate Cancer

10
11
12
13
14
15
16
17
18
19